A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria: Double-blind Treatment Period * Male or female at least 18 years of age * Subject must have had chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening visit * Subject must have Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5 point scale * Subject must be a candidate for systemic PSO therapy and/or phototherapy * Subject must be considered, in the opinion of the Investigator, to be a suitable candidate for treatment with secukinumab per regional labeling and has no contraindications to receive secukinumab as per the local label * Female subject of childbearing potential must be willing to use highly effective method of contraception Open-label extension (OLE) Period * Completed the double-blind Treatment Period without meeting any withdrawal criteria * All Week 48 visit assessments completed * Compliant with ongoing clinical study requirements * Signed a separate OLE Period Informed Consent Form (ICF) * Female subject of childbearing potential must be willing to use highly effective method of contraception OLE2 Period (USA and Canada) * Completed the OLE Period without meeting any withdrawal criteria * Compliant with ongoing clinical study requirements * Female subject of childbearing potential must be willing to use highly effective method of contraception * Subjects with a diagnosis of Crohn's disease or ulcerative colitis …